Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.
The submission is supported by efficacy and safety data from the Phase III VALOR clinical trial.
Lantheus's radiodiagnostic is designed to identify cognitively impaired patients who have tau neurofibrillary tangle (NFT) pathology.
Spevatamig is a bispecific antibody targeting claudin 18.2 and CD47, designed to function as an innate immunity enhancer.
Khartis was co-founded two years ago by the team at XinThera, a biotech acquired by Gilead.
In combination with ZDd, Zenbexus received the agency’s decision following results from the Phase III EXCALIBER-RRMM trial.
